Vitiligo - Vitiligen
☆ En els resultats de la Stiftung Warentest d'Alemanya de 2022, la satisfacció dels consumidors amb ModelDerm va ser només lleugerament inferior a la de les consultes de telemedicina de pagament.
El vitiligen dels dits és més difícil de tractar que altres zones. A part de ser cosmèticament antiestètic, el vitiligen és normal i no és contagiós. En dermatologia, el tractament més eficaç és la fototeràpia o el tractament amb làser (excimer) 2-3 vegades per setmana durant almenys 1 any. Si no podeu anar sovint a l'hospital per motius econòmics o perquè esteu ocupat, podeu provar una màquina de fototeràpia homologada per a ús domèstic.
Vitiligen de les parpelles
Vitiligo a mà
References
El vitiligen és un trastorn de la pell comú que provoca taques de pell blanca a causa de la pèrdua de melanòcits. Investigacions recents mostren que és una malaltia autoimmune. Tot i que sovint es considera un problema cosmètic, pot afectar profundament el benestar mental i la vida diària. L'any 2011, els experts van classificar un tipus anomenat segmental vitiligo per separat dels altres.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Els pacients amb vitiligen actiu tenen diverses opcions de teràpia, com ara glucocorticoides sistèmics, fototeràpia i immunosupressors sistèmics. Els pacients amb vitiligen estable poden trobar alleujament amb corticoides tòpics, inhibidors tòpics de calcineurina, fototeràpia i procediments de trasplantament. Els avenços recents en la comprensió dels processos subjacents del vitiligen han donat lloc al desenvolupament de teràpies dirigides. Actualment, els inhibidors de JAK són els més prometedors, oferint una bona tolerabilitat i resultats funcionals, malgrat el risc d'activar infeccions latents i efectes secundaris sistèmics comuns amb altres agents immunosupressors. La investigació en curs té com a objectiu identificar les citocines clau implicades en el desenvolupament del vitiligen (IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, TNF) . El bloqueig d'aquestes citocines s'ha mostrat prometedor en models animals i alguns pacients. A més, les investigacions sobre miRNA-based therapeutics i adoptive Treg cell therapy estan en curs.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
No hi ha cap cura coneguda per al vitiligen. Per a aquells amb pell clara, el protector solar i el maquillatge són tot el que es recomana. Altres opcions de tractament poden incloure cremes d'esteroides o fototeràpia.
○ Tractament
#Phototherapy
#Excimer laser
#Tacrolimus ointment